Free Medical Devices Simulation Webinar

Computational Simulation for Medical Devices
Jeff Crompton and Kyle Koppenhoefer founded AltaSim Technologies 15 years ago to help elevate our customers’ technology through the use of advanced computational simulation. Over the last 15 years, we’ve had the opportunity to work with amazing companies from all over the world to develop simulations that impacted their technologies. Many of these companies have designed medical products based on our models, and these models have supported submissions to the FDA. We have successfully assisted our customers with medical technology development in minimally invasive cardiovascular devices, imaging technology, surgical instruments, biotechnology, drug delivery, tissue ablation and diagnostic bioassays as well as other critical areas.We believe there are more companies that could benefit from computational simulations, and we are actively looking to identify those companies that are based in our home state of Ohio.
Computational simulation is widely used in many industries and is increasingly becoming important in the development of medical devices and life science applications.  It can help provide insight into device performance, exploration of design space, examine treatment efficacy, refine ideas faster and more accurately, and reduce expensive prototyping and testing. The FDA recognizes the value of computational simulation and has now begun actively encouraging its use to support device evaluation, verification and validation.
In this 30 minute webinar, we will discuss the benefits of computational simulation for medical devices, and demonstrate its use for devices requiring fluid transport, structural stability, electromagnetic interactions and biological materials. An overview of applications to several medical devices and life science applications will be discussed and at the end of the webinar a Q&A session will be available.
Register for our FREE 30-minute webinar on Wednesday, June 7th at 10:00am.  Seats in this webinar are limited.